See every side of every news story
Published loading...Updated

Study now recruiting patients to treat PANcreatic adenocarcinoma with Gemcitabine, Erlotinib, and nAb-paclitaxel (PANGEA) - UNC Lineberger

Summary by unclineberger.org
UNC Lineberger has opened a two-arm clinical trial to determine the optimal combination treatment for patients with advanced unresectable or metastatic basal-like subtype pancreatic ductal adenocarcinoma. The post Study now recruiting patients to treat PANcreatic adenocarcinoma with Gemcitabine, Erlotinib, and nAb-paclitaxel (PANGEA) appeared first on UNC Lineberger.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

unclineberger.org broke the news in on Friday, February 14, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.